Revolution Medicines completed the acquisition of EQRx for $1.1bn.

Revolution Medicines, a clinical-stage precision oncology company, completed the acquisition of EQRx, a biopharmaceutical company committed to developing and commercializing innovative medicines, for $1.1bn. “Revolution Medicines has reached an important milestone with the completion of this transaction that brings a significant additional quantum of capital to support our rapidly advancing clinical programs. We are also delighted to welcome Dr. Sandra Horning, a seasoned oncologist and late-stage clinical development leader, to the Revolution Medicines board of directors. We remain deeply committed to advancing our rich pipeline of promising oncology assets to address unmet patient needs, and I am extremely grateful to the employees and shareholders of Revolution Medicines and EQRx who have supported us to a successful transaction," Mark A. Goldsmith, Revolution Medicines CEO and Chairman.